Research and development of intelligent key technology and equipment of variable frequency moxibustion for obtaining gas and its demonstration application

Start Date06 May 2025

Sponsor / Collaborator-

NCT06721494

/ Not yet recruitingPhase 2

A Phase 2 Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine

The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).

Start Date01 Mar 2025

Sponsor / Collaborator

Clear Scientific, Inc.

[+1]

NCT05971043

/ Not yet recruitingNot ApplicableIIT

Skin Disorders in Patients Using Methamphetamine

1. To detect the skin diseases in patients using methamphetamine

Start Date03 Aug 2023

Sponsor / Collaborator

Assiut University

100 Clinical Results associated with Methamphetamine Hydrochloride

100 Translational Medicine associated with Methamphetamine Hydrochloride

100 Patents (Medical) associated with Methamphetamine Hydrochloride

18,900

Literatures (Medical) associated with Methamphetamine Hydrochloride

01 Oct 2025·Talanta

Screening and validation of sponge materials assembled to a sampling device for enrichment and determination of amphetamine drugs in exhaled breath by HPLC-TQ-MS/MS

Article

Author: Yang, Hai ; Yang, Xiangliang ; Xu, Fei ; Xu, Congfei ; Zhou, Jiedan ; Huang, Qingda ; Fan, Huajun

Exhaled breath aerosol (EBA) analysis of the amphetamine drugs (AMPs) and ephedrine (EPH) has a great potential to monitor illicit drug abuse due to its simple, non-invasive, convenient, and easily accepted sampling. Nevertheless, the extremely low concentration of AMPs and EPH in EBA poses great challenges to instrumental analysis. In this study, a self-designed sampling device equipped with sponge-based material was developed and coupled to high-performance liquid chromatography coupled with triple quadrupole tandem mass spectrometry (HPLC-TQ-MS/MS) for monitoring of the AMPs and EPH in EBA. Accordingly, the cellulose sponge with high adsorption performance and low expiratory resistance was screened out from multiple commercial sponges, optimized its configuration performance, and assembled to the sampling device, reaching the adsorption rates of 81.6 ± 2.2-98.9 ± 2.5 % for EPH and typical AMPs, including amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine, and 3,4-methylenedioxymethamphetamine. The combination of HPLC-TQ-MS/MS and the device containing cellulose sponge showed excellent analytical performance, with linearity in the range of 30.0-20000.0 pg/filter (R² ≥ 0.9901), low detection limit of 1.6-8.4 pg/filter, and the recoveries of 86.5-94.5 %. The device also exhibited good reusability and applicability for the simulated EBAs at different levels. Furthermore, the proposed method was successfully applied for determination of EPH in volunteers' EBAs, whose contents suggested a good correlation with that in saliva. Kinetic analysis provided insights into the adsorption mechanism, further validating reliability of the method. Overall, the simple, cheap, available, and reusable cellulose sponge assembled to sampling device was advantageous for enriching and monitoring of trace illicit drugs in human EBA.

01 Aug 2025·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

Sensitive SERS detection of trace methamphetamine in complex samples through sharp-spiked gold nanostructure

Article

Author: Su, Junyu ; Yang, Ruiqin ; Sun, Xin ; Wei, Wei ; Wang, Lei ; Zhao, Lingyi ; Li, Liming ; Zhang, Xiaowan ; Wang, Yong ; Wang, Chenchen

Taking a massive overdose of methamphetamine (MAMP), which is one of the most prevalent illicit drugs in the world, will stimulate central nervous system, impair both physical and mental health and even lead to death. Therefore, the rapid quantitative testing in the field of MAMP is of great importance to law enforcement agencies. In this study, a branched, sharp-spiked gold nanostructure, named AuNS@4-MBA, is successfully synthesized at room temperature. The quantitative detection of MAMP is achieved through surface-enhanced Raman scattering (SERS) using the AuNS@4-MBA substrate. Due to the unique morphology of the nanostructure, numerous "hot spots" are formed, providing optimal conditions for sensitive detection. Upon activation of the system using EDC/NHS, the SERS signal intensity at 1080 cm^-1 exhibits a gradual decrease as the MAMP concentration increases. This reduction can be attributed to the formation of amide compounds in the vicinity of 4-MBA, which not only interferes with the 4-MBA signal but also suppresses the aggregation of gold nanostars. Under optimized experimental conditions, the detection limit for MAMP was determined to be 1.3 × 10^-8 M (1.96 ng/mL), with a linear detection range spanning from 5 × 10^-8 M to 5 × 10^-4 M. Kinetic and isotherm analyses revealed that the capture of MAMP onto the AuNS@4-MBA surface follows pseudo-second-order kinetics and adheres to the Langmuir model. Furthermore, this highly accurate detection method demonstrates exceptional efficacy in complex biological and environmental matrices. Its universal applicability extends to the detection of illicit drugs containing amine groups, underscoring its potential as a robust tool for forensic analysis and rapid on-site drug screening at crime scenes.

01 Jul 2025·Forensic Chemistry

Analysis of substituted Cathinones and fentanyl analogs by gas chromatography-infrared spectroscopy (GC-IRD) using nitrogen carrier gas

Author: Warner, Marcus L.

Substituted cathinones and fentanyl analogs that are positional isomers can produce similar mass spectra and retention times, which poses challenges for their identification.A gas chromatog.-IR spectroscopy (GC-IRD) method, developed using nitrogen as the carrier gas, was employed as a complimentary technique to gas chromatog.-mass spectroscopy (GC-MS) for the accurate identification of positional isomers.Due to the global helium shortage and since Agilent helium (nitrogen switch) conservation modules were currently in use, nitrogen was selected and a novel method was developed for the anal. of controlled substances.A total method run time of 26 min for the anal. of 29 certified reference materials comprised of substituted cathinones and fentanyl analogs was achieved.A drug mixture was also analyzed to evaluate the resolution and retention time.Standards were prepared at concentrations of 100 μg/mL, 1 mg/mL and 2 mg/mL and analyzed over a 3-day period, where the 2 mg/mL concentrations of the standards were run in triplicate on day 1 and once on days 2 and 3.Twenty-seven of the standards were identified with a library match of 0.98 or higher for the 1 mg/mL concentrationEach standard experienced a retention time (RT) coefficient of variation (%CV) less than 3 %.For the drug mixture peak resolution exceeded 1.5 for each component.The GC-IRD validated method was found to be a suitable complementary anal. technique to GC-MS for analyzing substituted cathinones and fentanyl analogs, as demonstrated by the repeatable and reproducible RTs and library matches obtained during method validation.

News (Medical) associated with Methamphetamine Hydrochloride

28 Apr 2025

·www.prnewswire.com

Myosin Therapeutics Awarded $3 Million NIH Grant to Advance Clinical Trial for MT-110 in Methamphetamine Use Disorder

JUPITER, Fla., April 28, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a biotechnology company developing innovative therapies for cancer and neurological disorders, today announced that it has been awarded a $3 million grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). This grant will help support the initiation of a Phase 1 clinical trial to assess the safety, tolerability, and pharmacokinetics of MT-110, laying the foundation for MT-110 as a first-in-class treatment option for methamphetamine use disorder (MUD). MUD is a severe and growing public health crisis with no FDA approved treatments. In the United States alone, over 2.5 million people are estimated to have this use disorder. And, unlike opioids, the number of overdose deaths attributed to methamphetamine increased last year. The NIDA grant is part of the Small Business Innovation Research (SBIR) program, which supports early-stage companies advancing technologies with strong public health potential. This highly competitive program is a critical pathway for accelerating translational science in areas of significant unmet medical need, including substance use disorders. "We are extremely grateful to NIDA for their continued support of this program," said Dr. Pat Griffin, co-founder of Myosin Therapeutics. "There are currently no FDA-approved medications for methamphetamine use disorder, and we believe MT-110 has the potential to fill this critical unmet need." MT-110 was developed through NIH's Blueprint Neurotherapeutics Network, a public-private partnership that helped Myosin Therapeutics' co-founders advance MT-110 from discovery through preclinical development. MT-110 targets a molecular nanomotor protein to reduce the motivation for stimulants and prevent relapses without impacting natural rewards. Preclinical studies have shown excellent safety and efficacy, supporting its advancement into human trials. "Methamphetamine use disorder devastates lives and communities, and current treatment options are limited to behavior modification therapies," said Dr. Karen Smith, Chief Medical Officer of Myosin Therapeutics. "MT-110's long-lasting efficacy in preclinical studies following just a single administration makes it particularly promising, as a daily medication can be challenging for this population." About Myosin Therapeutics Myosin Therapeutics is a Jupiter, FL-based biotechnology company spun out of The Wertheim UF Scripps Institute. The company develops novel therapies for neuroscience and oncology indications using a discovery platform focused on molecular nanomotor proteins. Myosin Therapeutics was founded in 2020 by Drs. Courtney Miller, Patrick Griffin, and Theodore Kamenecka. For more information, visit . Contact: [email protected] SOURCE Myosin Therapeutics Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 1

22 Apr 2025

·www.globenewswire.com

Intelligent Bio Solutions Expands Global Reach with Latin American Spanish Language Integration into Drug Screening System

Company expands Intelligent Fingerprinting Drug Screening System multilingual capabilities to meet growing demand across Latin American Spanish-speaking markets Latin American drug screening market projected to reach USD 1.1 billion by 2030 Expansion is part of major multilingual Drug Screening System upgrade, targeting over 4 billion potential users worldwide NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the integration of Latin American Spanish into its Intelligent Fingerprinting Drug Screening System (the “System”). The enhancement allows users to operate the System in English, Arabic, and Latin American Spanish, extending the platform’s usability across diverse, international settings. Spanish is the fourth most spoken language in the world and the second most spoken language in the U.S. It is the official language in over 20 countries, including the majority of countries in Latin America, and is spoken by over 500 million people globally1. By incorporating Latin American Spanish into the System, INBS strengthens its support for Spanish-speaking markets and regional distribution partners. This update increases accessibility for end-users across North America, Central America, South America, and Europe, aligning with the Company’s strategic growth plans. “As we see increased interest from Spanish-speaking distributors and companies, we must ensure our solution remains accessible and relevant to these markets. Integrating Latin American Spanish into our System is a key step toward opening new opportunities for future growth,” said Harry Simeonidis, President & CEO at Intelligent Bio Solutions. “As demand grows, so does the value of business localization. Our product stands out in the market by offering local language capabilities, something most solutions don’t provide. It’s a clear differentiator.” The Latin American drug screening market is projected to reach USD 1.1 billion by 2030, driven by increasing public safety initiatives and growing demand for workplace compliance programs2. In Europe, Spain’s drug testing market is expected to reach USD 368.4 million by 20303, reflecting similar trends in regulation and adoption. INBS’ multilingual capabilities position the Company to better serve evolving testing needs through an intuitive, localized platform experience. This development forms part of the Company’s major multilingual system upgrade announced earlier this year. The complete multilingual upgrade will support multiple languages spoken across the Americas, Europe, Asia Pacific and the Middle East, making the System accessible to over 4 billion speakers worldwide4. The added capability supports a broader growth strategy to expand on a foundation of over 400 accounts across 19 countries and to penetrate new markets and regions. The Latin American Spanish enhancement is a key development milestone as the Company prepares to enter the multi-billion-dollar U.S. market this year, following its FDA 510(k) submission in December 2024. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. For more information, visit: http://www.ibs.inc/ Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact:   Intelligent Bio Solutions Inc.  info@ibs.inc   LinkedIn | Twitter  Investor & Media Contact: Valter Pinto, Managing Director KCSA Strategic Communications PH: (212) 896-1254 INBS@kcsa.com _____________________________ Hyperlinks and website references in this release are provided for convenience only, and do not incorporate the referenced content into this release. 1 Statista 2025. Countries with the largest number of native Spanish speakers worldwide in 2024. Available at: https://www-statista-com.libproxy1.nus.edu.sg/statistics/991020/number-native-spanish-speakers-country-worldwide/ 2 Grand View Research 2025. Latin America Drug Screening Market Size & Outlook. Available at: https://www.grandviewresearch.com/horizon/outlook/drug-screening-market/latin-america3 Grand View Research 2025. Spain Drug Screening Market Size & Outlook, 2018-2030. Available at: https://www.grandviewresearch.com/horizon/outlook/drug-screening-market/spain 4 Ethnologue, 2024. The Ethnologue 200. Available at: https://www.ethnologue.com/insights/ethnologue200/

31 Mar 2025

·www.globenewswire.com

Intelligent Bio Solutions Expands Middle East Market Reach with Arabic Integration in Drug Screening System

Integration of Arabic opens opportunities in the Middle East and supports Company’s strategic global expansion goalsNEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has integrated Arabic as the second international language to its Intelligent Fingerprinting Drug Screening System as part of the Company’s multilingual upgrade. The addition of Arabic follows INBS’s previously announced expansion plans in the Middle East in early 2025, through its partnership with Ivy Diagnostics. Arabic is spoken by approximately 450 million people worldwide, holding official status in nearly 25 countries1. With this update, INBS is making its technology more accessible to Arabic-speaking organizations in safety-critical industries, law enforcement and drug rehabilitation, reinforcing its presence in the Middle East and capitalizing on the growing global demand for innovative drug testing solutions. Integrating the Arabic language into the Company’s portable Drug Screening Reader will improve accessibility and usability for Arabic-speaking organizations in the Middle East. With the workplace drug testing market in Saudi Arabia alone projected to reach $64.5 million by 2030, INBS is well-positioned to meet the growing demand for accessible, efficient, and reliable drug testing solutions across the Middle East2. This update will allow for the smooth integration of the Company’s technology into existing safety protocols, enabling businesses to strengthen workplace safety standards. “Expanding language support is a crucial step in ensuring our expanded global reach and accessibility of our solution to organizations worldwide,” said Harry Simeonidis, President & CEO of Intelligent Bio Solutions Inc. “Arabic was a logical choice for the second language integrated into our system, given its wide use across the globe. Adding Arabic to our system strengthens our capabilities and presence in the Middle East and will provide more businesses with an intuitive and reliable drug testing solution.” The integration of Arabic language marks a key milestone in INBS’ broader international growth strategy, reinforcing its footprint in key markets. The enhancement aligns with the Company’s plans to scale operations across North and South America, Europe, Asia Pacific and the Middle East, expanding on its existing presence in 19 countries. This update builds on INBS’ strategic milestones, including its recent FDA 510(k) submission in December 2024 and planned entry into the multi-billion dollar U.S. market in 2025. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. For more information, visit: http://www.ibs.inc/. Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact:   Intelligent Bio Solutions Inc.  info@ibs.inc   LinkedIn | Twitter  Investor & Media Contact:  Valter Pinto, Managing Director  KCSA Strategic Communications  PH: (212) 896-1254  INBS@kcsa.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/79dc5c7a-6775-4030-841e-7922be3fea9a Hyperlinks and website references in this release are provided for convenience only, and do not incorporate the referenced content into this release. 1 United Nations 2024. World Arabic Language Day, 18 December. Available at: https://www-un-org.libproxy1.nus.edu.sg/en/observances/arabiclanguageday/ 2 Grand View Research, 2024. Saudi Arabia Employer And Workplace Drug Testing Market Size & Outlook Available at: https://www.grandviewresearch.com/horizon/outlook/employer-and-workplace-drug-testing-market/saudi-arabia/

100 Deals associated with Methamphetamine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Methamphetamine Hydrochloride	N06BA03	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Attention Deficit Disorder With Hyperactivity	United States	AJENAT PHARMACEUTICALS LLC	31 Dec 1943
Depressive Disorder	Japan	Sumitomo Pharmaceuticals Co., Ltd.	01 Jan 1941
Narcolepsy	Japan	Sumitomo Pharmaceuticals Co., Ltd.	01 Jan 1941
Schizophrenia	Japan	Sumitomo Pharmaceuticals Co., Ltd.	01 Jan 1941

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03825536 (EMRLHD, CTgov)	Phase 4	Methamphetamine dependence \| HIV Infections	14	Placebo oral capsule+Oral Methamphetamine (Oral Methamphetamine, Then Placebo Oral Capsule)	fduteuhddw(qmcngzctrr) = clegsoqycz fyjudknybg (okzqbcwesf, ufbngthelc - jipviwerum)	-	08 Apr 2025
				Placebo oral capsule+Oral Methamphetamine (Placebo Oral Capsule, Then Oral Methamphetamine)	fduteuhddw(qmcngzctrr) = pfatfanntp fyjudknybg (okzqbcwesf, spmsuultqq - wapiruynpu)
NCT04642820 (DDP, CTgov)	Early Phase 1	-	138	placebo oral tablet+Methamphetamine (Placebo Then Methamphetamine)	tdiabknqjm(pfsdwwaohm) = fsvpeqgjhp pstbehlfxg (kqerbxhrai, btasekjsbx - cymxyougij) View more	-	09 Jan 2025
				placebo oral tablet+Methamphetamine (MethamphetamineThen Placebo)	tdiabknqjm(pfsdwwaohm) = zpltmuoxlt pstbehlfxg (kqerbxhrai, qgkniulfnc - rdsopvdlwa) View more
NCT03790618 (ESP, CTgov)	Phase 1	-	36	3,4-Methylenedioxymethamphetamine+methamphetamine (Placebo)	zdrugqxorl(aelocdvegd) = yptqdhtfey fjnarvgxcd (ifmmzuammm, udfxapbjnl - ujzcjnflfv) View more	-	05 Jan 2024
				3,4-Methylenedioxymethamphetamine+methamphetamine (Low Dose MDMA)	zdrugqxorl(aelocdvegd) = pcjxjkbqwk fjnarvgxcd (ifmmzuammm, mhvfkxjzmf - binjlsdxyc) View more
NCT04178993 (CTgov)	Phase 1	Methamphetamine dependence	8	Placebo oral capsule+Methylphenidate+Methamphetamine (Placebo Comparator: Placebo)	wrvewzrffq(rzgpisvueg) = glrwxyxwew seaynupgvf (busxskapdx, rjutslbvav - eihhvctjpe) View more	-	09 Jan 2023
				Placebo oral capsule+Methylphenidate+Duloxetine+Methamphetamine (Active Comparator: Duloxetine)	arvsoeaedv(axamyzccnc) = mxpozhxzpn cjhjjrtwob (sshmrsxesq, qpnimngyfc - mgnoakwkju) View more
SFN2021	Not Applicable	-	-	Methamphetamine	tvuxsavtxm(wbfywvgnzg) = 0.1 mg/kg LEV increased the time spent in the drug-paired chamber, but this data did not reach statistical significance dcnkxohzye (wreycouwzi )	-	11 Nov 2021
				Levamisole
SFN2018	Not Applicable	Methamphetamine dependence	-	Methamphetamine 0.3 mg/kg	zimdxevhjs(abtcatfujj) = nqyvandpjw lqircfxxpv (homzhoitxf )	-	03 Nov 2018
				Methamphetamine 2.0 mg/kg	zimdxevhjs(abtcatfujj) = cqmddgbnlq lqircfxxpv (homzhoitxf )
NCT02323048 (CAM, CTgov)	Not Applicable	Substance Abuse	90	placebo+methamphetamine (Paired, Low Reward)	inzuljnodw(ldbypukxzr) = iexowrrvty vbfurpomal (xrnqftbjoe, kkxzojmxmo - kcjcvxotdq) View more	-	26 Jul 2018
				placebo+methamphetamine (Paired, High Reward)	inzuljnodw(ldbypukxzr) = slhjtlisld vbfurpomal (xrnqftbjoe, qbhedgclla - hwyxgrqwvv) View more
SFN2017	Not Applicable	Toxicity	-	Alcohol	ugoipdahpe(vtmzqkxfcs) = rhqazysrug rnvgbkwtlp (lhmzjajqjc ) View more	-	11 Nov 2017
				Methamphetamine	kwdjqiqjbr(jcqpmmnsbo) = jmalbihedu ugkcelmdki (vbxyalyjrx ) View more
SFN2015	Not Applicable	Methamphetamine dependence	-	Methamphetamine 1.0 mg/kg	pnovxgureh(pqlqwzcckc) = jiubnnnmov hkfzczwgye (wquycyflho )	-	19 Oct 2015
				Methamphetamine 2.0 mg/kg	cyaytofkro(maeknsbens) = rtiyqvwkfy dcxhdblmhx (ldqbgoatjy )
ISC2013	Not Applicable	Cerebral Hemorrhage methamphetamine abuse	384	Methamphetamine (Native Hawaiians and other Pacific Islanders)	atylqypqum(aoblzliqns) = gztvqwvrgc wthbfktose (ylgvghpzkx ) View more	-	01 Feb 2013
				Methamphetamine (Non-Hispanic whites)	atylqypqum(aoblzliqns) = upxpjgcwyb wthbfktose (ylgvghpzkx ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Methamphetamine Hydrochloride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation